Exclusive
Release Date
How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost)
How Did MFN Turn Swiss Pricing into an Industrial Policy Problem, Dr. Marcel Boller?
Is the EU "Launch Obligation" Really as Scary as It Sounds, Dr. Alexander Natz?
Dynamic Rebates, Drug Tenders & AMNOG: Is Germany Rewriting the Rules for Pharma, Thomas Hammerschmidt?
Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour?